Register for our free email digests:
Latest From BioLineRx Ltd.
Pipeline Watch: Phase III Starts With Fitusiran In Hemophilia, Zoliflodacin In Gonorrhea, Opdivo Combo In RCC
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Free article: In Vivo's editors pick March's most significant deals, including Spero's Series C and Allergan's deal with Editas.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in March 2017.
BioLineRx buys Agalimmune and its alpha Gal candidate for melanoma and possibly other oncology indications. Japan's Ono signs an R&D agreement with Switzerland's Numab, while Boston biotechs Vedantra and Neon will collaborate on potential cancer vaccines.
- Specialty Pharmaceuticals
- Therapeutic Areas
- Hepatic (Liver)
- Metabolic Disorders
- Bioline Therapeutics
- Middle East
- Parent & Subsidiaries
- BioLineRx Ltd.
- Senior Management
Philip A Serlin, CEO
Mali Zeevi, CFO
David Malek, CBO
Ella Sorani, PhD, VP, Dev.
- Contact Info
Phone: (972) 8 642 9100
Modi’in Technology Park
2 HaMa’ayan St.
P.O. Box 45158 Modi’in , 7177871
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.